These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29083466)

  • 1. Pneumonitis From Anti-PD-1/ PD-L1 Therapy.
    Balaji A; Verde F; Suresh K; Naidoo J
    Oncology (Williston Park); 2017 Oct; 31(10):739-46, 754. PubMed ID: 29083466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
    Naidoo J; Wang X; Woo KM; Iyriboz T; Halpenny D; Cunningham J; Chaft JE; Segal NH; Callahan MK; Lesokhin AM; Rosenberg J; Voss MH; Rudin CM; Rizvi H; Hou X; Rodriguez K; Albano M; Gordon RA; Leduc C; Rekhtman N; Harris B; Menzies AM; Guminski AD; Carlino MS; Kong BY; Wolchok JD; Postow MA; Long GV; Hellmann MD
    J Clin Oncol; 2017 Mar; 35(7):709-717. PubMed ID: 27646942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
    Nishino M; Chambers ES; Chong CR; Ramaiya NH; Gray SW; Marcoux JP; Hatabu H; Jänne PA; Hodi FS; Awad MM
    Cancer Immunol Res; 2016 Apr; 4(4):289-93. PubMed ID: 26865455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.
    Gounant V; Brosseau S; Naltet C; Opsomer MA; Antoine M; Danel C; Khalil A; Cadranel J; Zalcman G
    Lung Cancer; 2016 Sep; 99():162-5. PubMed ID: 27565934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice.
    Hamada N; Yanagihara T; Suzuki K; Ogata-Suetsugu S; Harada E; Mikumo H; Arimura-Omori M; Nakanishi Y
    Biochem Biophys Res Commun; 2017 Sep; 491(3):656-661. PubMed ID: 28756224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
    Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
    Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
    Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 13. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
    Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Yatabe Y; Hida T
    Lung Cancer; 2018 Nov; 125():212-217. PubMed ID: 30429022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Pneumonitis with the Use of Different Immune Checkpoint Inhibitors in a Mexican Population.
    Dávila-Dupont D; Motola-Kuba D; Dorantes-Heredia R; González-Alonso BK; Alcántara-Velarde T; García-Santisteban R; Martínez-Sámano JE; Grimaldo-Roque HJ; Ruiz-Morales JM
    Oncology; 2019; 96(5):268-272. PubMed ID: 30861515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy-induced pneumonitis: cases report.
    Helber HA; Hada AL; Pio RB; Moraes PHZ; Gomes DBD
    Einstein (Sao Paulo); 2018 Jun; 16(2):eRC4030. PubMed ID: 29947645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
    Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
    Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
    He J; Hu Y; Hu M; Li B
    Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature.
    Liang X; Guan Y; Zhang B; Liang J; Wang B; Li Y; Wang J
    Front Oncol; 2019; 9():1437. PubMed ID: 31921686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.